Treanda - Myeloma Experimental Treatment - Experimental Drugs


What is Treanda?

Treanda (also known as bendamustine) is an intravenous chemotherapy agent. It is thought to kill tumor cells by damaging their DNA, but is also similar in structure to another class of cancer drugs and may have other anti-tumor effects.

Bendamustine is approved for the treatment of myeloma in Germany under the name Ribomustin and has been used there for many years. Treanda, made by Cephalon Oncology in the US, is currently FDA-approved for the treatment of two other blood cancers. Since Treanda is available in the US, doctors may prescribe it for other conditions, such as multiple myeloma, based on the existing data supporting its effectiveness.

The Multiple Myeloma Research Consortium (MMRC) supports the development of bendamustine in multiple myeloma in the US and is currently facilitating a trial evaluating bendamustine in combination with another myeloma agent.